Clinico-Epidemiologic Characteristics of Patients Reported in the Mycotic Infections in COVID-19 Registry

Am J Trop Med Hyg. 2022 Dec 19;108(3):584-587. doi: 10.4269/ajtmh.22-0503. Print 2023 Mar 1.


We update results from the Mycotic Infections in COVID-19 (MUNCO) Registry, May-September 2021. Data collection from May to September 2021 yielded 728 cases from India, Nepal, Bangladesh, Thailand, and the United States. The cases consisted of mostly mucormycosis (97.6%), primarily rhinocerebral, and were analyzed to investigate clinical characteristics associated with negative outcomes. Patients were mostly diabetic (85%) and male (76%), with significant mortality (11.7%). All patients received treatment of coronavirus disease 2019 (COVID-19) as well as antifungal treatment. The crude mortality rate was 11.3% for mucormycosis and 22.7% formixed infections. This study demonstrates the utility of online databases in the collection of high-caliber data.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antifungal Agents / therapeutic use
  • COVID-19* / complications
  • Diabetes Mellitus* / drug therapy
  • Humans
  • Male
  • Mucormycosis* / drug therapy
  • Registries


  • Antifungal Agents